University of Queensland researchers' call for tighter controls on injectable peptides, published as an expert commentary in The Lancet Child & Adolescent Health (2026), correctly flags social-media-driven demand and clinician unpreparedness but overlooks how this Australian surge mirrors global patterns of self-experimentation in performance and anti-aging markets. The piece, an observational expert opinion without original data collection or sample size, notes risks of infection and dosing errors yet understates connections to broader body-image pressures and the absence of randomized controlled trials evaluating long-term safety of compounds like BPC-157 or TB-500. A 2022 systematic review in Sports Medicine (n=47 studies, mostly small observational cohorts with industry funding conflicts) found limited evidence for muscle-growth peptides beyond short-term anabolic effects, echoing steroid-era harms documented in a 2019 Australian observational study of 1,200 users. These sources reveal what the original coverage misses: profit-driven online sales exploit regulatory loopholes where peptides are sold as 'research chemicals,' bypassing Therapeutic Goods Administration oversight and enabling off-label use without sterility standards. Self-experimentation now outpaces safety data, as wellness optimization culture prioritizes rapid aesthetic results over peer-reviewed validation, creating parallel markets to anabolic-androgenic steroids that Steroid QNECT programs have only begun to address through harm reduction.